| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 4/6 |
Stryker Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$321.70 |
| 52 Week High | US$333.60 |
| 52 Week Low | US$240.10 |
| Beta | 0.91 |
| 1 Month Change | -2.31% |
| 3 Month Change | 13.31% |
| 1 Year Change | 22.79% |
| 3 Year Change | 50.61% |
| 5 Year Change | 103.97% |
| Change since IPO | 764.78% |
Recent News & Updates
Recent updates
Shareholder Returns
| SYK | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -0.8% | -1.9% | -0.9% |
| 1Y | 22.8% | -2.5% | 3.3% |
Return vs Industry: SYK exceeded the German Medical Equipment industry which returned -2.5% over the past year.
Return vs Market: SYK exceeded the German Market which returned 3.3% over the past year.
Price Volatility
| SYK volatility | |
|---|---|
| SYK Average Weekly Movement | 2.8% |
| Medical Equipment Industry Average Movement | 5.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 9.7% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: SYK has not had significant price volatility in the past 3 months.
Volatility Over Time: SYK's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1941 | 52,000 | Kevin Lobo | www.stryker.com |
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.
Stryker Corporation Fundamentals Summary
| SYK fundamental statistics | |
|---|---|
| Market cap | €123.11b |
| Earnings (TTM) | €2.95b |
| Revenue (TTM) | €19.11b |
41.7x
P/E Ratio6.4x
P/S RatioIs SYK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SYK income statement (TTM) | |
|---|---|
| Revenue | US$20.50b |
| Cost of Revenue | US$7.40b |
| Gross Profit | US$13.10b |
| Other Expenses | US$9.93b |
| Earnings | US$3.17b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 30, 2024
| Earnings per share (EPS) | 8.32 |
| Gross Margin | 63.89% |
| Net Profit Margin | 15.44% |
| Debt/Equity Ratio | 69.9% |
How did SYK perform over the long term?
See historical performance and comparison